Prothena

Pipeline treatments in 7MM prioritize disease-modifying therapies (DMTs) and non-motor symptom therapies for Parkinson’s disease, with 66% of 93 Phase I-III products targeting neuroprotective agents. Key agents include Annovis Bio’s Posiphen and BioVie’s Triolex. Research also focuses on Parkinson’s disease dementia and psychosis, aiming to improve both motor and non-motor symptoms.

Tau Inhibitors Clinical Trial Pipeline Analysis shows 25+ key companies expected to transform treatment, with increased funding accelerating advancements in neurodegenerative disease therapies.

John Mulcahy, CEO of SiteOne Therapeutics, notes pain treatment's recent industry resurgence. The company aims to use new funding to achieve 'proof of concept' for its pain medicines.

Biogen and Eisai's Alzheimer's drug Leqembi received full FDA approval, enabling broader Medicare coverage. Novavax's stock surged after amending its vaccine deal with Canada, involving a $349.6M payment. Caribou Biosciences gained from Pfizer's $25M investment, advancing its CAR-T cell therapy. Prothena secured a $55M deal with Bristol Myers Squibb for Alzheimer's treatment rights.

Recent breakthroughs in Alzheimer's treatment, notably lecanemab's FDA approval and donanemab's Phase 3 trial success, offer new hope for patients and investment opportunities. Despite challenges in access and infrastructure, these developments mark a significant step forward in combating Alzheimer's, promising better outcomes and reducing healthcare burdens.